ストックスクリーナーアプリを入手
10.00
4.38%
0.42
プレマーケット:
10.00
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 7.8%Should You Sell? - MarketBeat
Q2 EPS Estimate for ORIC Pharmaceuticals Reduced by Analyst - Defense World
Q2 EPS Forecast for ORIC Pharmaceuticals Reduced by Analyst - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.29 - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 10.9% HigherTime to Buy? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Oric Pharmaceuticals announces clinical supply agreement with Janssen - Yahoo Finance
Barclays PLC Raises Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives Buy Rating from HC Wainwright - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives Outperform Rating from Wedbush - Defense World
ORIC Pharmaceuticals advances cancer drug trials - Investing.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Outperform Rating from Wedbush - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpHere's What Happened - MarketBeat
ORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
ORIC Pharmaceuticals, Inc. Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLCwith EGFR Exon 20 Insertion Mutations - Marketscreener.com
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations - The Manila Times
ORIC® Pharmaceuticals Provides Early Phase 1b Combination - GlobeNewswire
ORIC Pharmaceuticals Announces Clinical Supply Agreement to - GlobeNewswire
ORIC Pharma's Cancer Drug Shows Strong Early Results, Partners With J&J for Lung Cancer Trial - StockTitan
ORIC Partners with Janssen to Test ORIC-114 Combo Therapy for First-Line NSCLC Treatment - StockTitan
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Analysts - MarketBeat
ORIC Pharmaceuticals (STU:4TZ) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 8.8%Here's Why - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Jane Street Group LLC - Defense World
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
(ORIC) Proactive Strategies - Stock Traders Daily
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Awards Inducement Grants to New Employee, Including Stock Options - StockTitan
Geode Capital Management LLC Boosts Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Barclays PLC Has $1.10 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
(ORIC) Trading Signals - Stock Traders Daily
EGFR-Non Small Cell Lung Cancer Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | AstraZeneca, J&J Innovative Medicine, Hansoh Pharma, Cullinan Oncology, Taiho Pharma - The Globe and Mail
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownHere's Why - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 3.4%Should You Sell? - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by State Street Corp - Defense World
State Street Corp Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Holdings Raised by Franklin Resources Inc. - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by XTX Topco Ltd - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $236,000 Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.29 Average Target Price from Analysts - Defense World
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.29 - MarketBeat
Oric Pharmaceuticals CEO Chacko Jacob sells $204,214 in stock By Investing.com - Investing.com South Africa
Dominic Piscitelli Sells 8,851 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
Pratik S. Multani Sells 8,850 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Sells $204,184.80 in Stock - MarketBeat
Oric Pharmaceuticals chief medical officer sells $73,293 in stock - Investing.com India
Oric Pharmaceuticals chief medical officer sells $73,293 in stock By Investing.com - Investing.com Australia
Oric Pharmaceuticals CFO sells $73,297 in stock - Investing.com India
Oric Pharmaceuticals CFO sells $73,297 in stock By Investing.com - Investing.com Australia
Oric Pharmaceuticals CEO Chacko Jacob sells $204,214 in stock - Investing.com
(ORIC) Technical Data - Stock Traders Daily
4.81%
大文字化:
|
ボリューム (24 時間):